long
discoveri
specif
gene
caus
diseas
year
prior
public
dna
structur
dr
jame
watson
dr
franci
crick
dr
clyde
e
keeler
predict
gene
therapi
would
therapeut
techniqu
achiev
perman
correct
hereditari
diseas
sever
year
later
dr
theodor
friedmann
dr
richard
roblin
predict
gene
therapi
may
amelior
human
genet
diseas
futur
true
predict
gene
therapi
vector
subject
extens
develop
last
year
effort
insert
replac
therapeut
gene
target
cell
affect
tissu
cure
genet
diseas
proofofprincipl
gene
therapi
becam
realiti
ashanti
desilva
suffer
adenosin
deaminas
sever
combin
immunodefici
ada
scid
subject
ex
vivo
gene
therapi
trial
subset
cell
remov
treat
ex
vivo
gammaretroviru
express
ada
gene
genecorrect
cell
reintroduc
circul
process
essenti
reconstitut
immun
system
genecorrect
cell
ashanti
healthi
deliveri
express
therapeut
gene
affect
tissu
organ
hold
great
promis
treatment
variou
lifethreaten
acquir
inherit
diseas
affect
human
gene
therapi
simpl
concept
deliveri
dna
rna
affect
somat
cell
specif
tissu
organ
repair
defect
restor
normal
function
cure
subject
specif
diseas
phenotyp
almost
year
ago
cystic
fibrosi
cf
airway
diseas
character
excel
candid
gene
therapi
basi
monogen
diseas
level
gene
express
necessari
correct
diseas
phenotyp
low
adenovirus
adv
nonenvelop
virus
linear
doublestrand
dna
genom
belong
adenovirida
famili
adenovirus
common
pathogen
respiratori
tract
account
upper
respiratori
infect
young
children
older
adult
given
larg
clone
capac
kb
develop
gene
therapi
vector
variou
genet
diseas
includ
cf
although
serotyp
adv
vector
base
serotyp
member
subgroup
c
extens
report
effici
transfer
transgen
mani
cell
type
vitro
variou
tissu
organ
vivo
adv
vector
produc
high
titer
minim
risk
contamin
replicationcompet
viru
howev
adv
vector
nonintegr
nonrepl
confer
transient
gene
express
durat
depend
prolifer
state
target
cell
adv
four
earli
gene
encod
polypeptid
respons
viral
cellular
gene
express
viral
replic
repress
major
histocompat
complex
respons
inhibit
cellular
apoptosi
firstgener
adv
vector
earli
region
contain
transcript
regulatori
gene
essenti
viral
replic
replac
express
cassett
transgen
adv
vector
propag
cell
line
administr
firstgener
adv
vector
anim
subject
gene
therapi
clinic
trial
found
elicit
high
inflammatori
immun
respons
respons
cellmedi
direct
vector
transgen
product
result
elimin
transduc
cell
compromis
durat
gene
express
second
gener
adv
vector
addit
region
region
either
delet
disabl
consequ
adv
vector
exhibit
lower
level
viral
protein
express
shown
respons
evok
host
immun
inflammatori
respons
gene
transfer
effici
secondgener
adv
vector
differ
firstgener
adv
vector
effort
improv
durat
gene
express
safeti
helperdepend
adv
vector
develop
vector
devoid
viral
code
sequenc
integr
host
genom
result
longterm
gene
express
vivo
semin
moment
clinic
translat
gene
therapi
seriou
advers
event
occur
clinic
trial
ornithin
transcarbamylas
defici
death
mr
jess
gelsing
enrol
sixth
cohort
studi
receiv
highest
dose
adv
vector
patient
suffer
acut
sever
inflammatori
respons
result
death
almost
day
vector
inject
unfortun
outcom
trial
sever
dampen
enthusiasm
gene
therapi
posit
way
howev
event
serv
refocu
attent
field
host
immun
respons
viral
capsid
well
express
therapeut
transgen
product
pave
way
futur
gene
therapi
success
adenoassoci
viru
aav
discov
contamin
adv
vector
stock
prepar
found
requir
presenc
adv
herpesviru
replic
vitro
aav
nonenvelop
singlestrand
dna
viru
belong
parvovirida
famili
clone
capac
aav
kb
limit
develop
genet
diseas
requir
express
larg
therapeut
transgen
cf
gene
cystic
fibrosi
transmembran
conduct
regul
cftr
cf
airway
diseas
aav
vector
posit
transduc
divid
nondivid
cell
advantag
organ
cell
activ
divid
eg
lung
date
aav
associ
known
human
diseas
consid
safe
vector
use
human
overcom
depend
secondstrand
synthesi
selfcomplementari
aav
scaav
vector
develop
two
main
benefit
vector
rapid
onset
gene
express
significantli
higher
level
transgen
express
compar
singlestrand
counterpart
howev
main
disadvantag
associ
use
scaav
vector
reduc
clone
capac
kb
contrast
wildtyp
aav
integr
specif
q
arm
chromosom
aav
vector
includ
scaav
integr
randomli
rais
possibl
insert
mutagenesi
remain
stabl
episom
dna
recent
year
demonstr
aav
vector
preferenti
integr
activ
gene
follow
system
deliveri
mous
liver
rais
potenti
cancer
develop
aav
vectormedi
integr
howev
common
observ
retrovirus
aav
vector
possess
machineri
necessari
activ
gene
caus
break
host
chromosom
subsequ
larg
longterm
liverdirect
gene
transfer
studi
mice
evid
tumorigenesi
addit
liver
tumor
observ
longterm
monkey
studi
jame
wilson
univers
pennsylvania
person
commun
canin
aavbas
liverdirect
gene
transfer
studi
respect
safeti
profil
aav
vector
inject
subject
seriou
advers
event
report
except
death
young
woman
enrol
gene
therapi
clinic
trial
rheumatoid
arthriti
trial
vector
express
tumor
necrosi
factor
alpha
inhibitor
inject
intraarticularli
one
knee
enrol
subject
femal
subject
receiv
second
vector
inject
month
follow
first
inject
howev
die
within
day
inject
detail
postmortem
examin
subject
extens
review
expert
panel
conven
nih
recombin
dna
advisori
committe
conclud
death
subject
relat
aav
vectorinfus
rather
due
dissemin
fungal
infect
six
aav
vector
serotyp
aav
differ
tropism
transduct
effici
properti
preclin
clinic
studi
focus
prototyp
aav
serotyp
sinc
aav
vector
toolkit
significantli
enrich
isol
character
novel
serotyp
featur
new
tropism
improv
transduct
safeti
profil
well
scalabl
manufactur
protocol
clinic
trial
one
serotyp
discov
laboratori
jame
wilson
extens
studi
liverdirect
gene
transfer
clinic
util
current
assess
numer
preclin
clinic
studi
treatment
variou
genet
diseas
includ
famili
hypercholesterolemia
hemophilia
b
ornithin
transcarbamylas
defici
duchenn
muscular
dystrophi
dmd
current
clinic
trial
use
variou
aav
vector
treat
specif
genet
diseas
disord
importantli
efficaci
vari
level
report
gene
therapi
clinic
trial
leber
congenit
amaurosi
lca
parkinson
diseas
hemophilia
b
lipoprotein
lipas
lpl
defici
retroviru
envelop
singlestrand
rna
viru
belong
retrovirida
famili
moloney
murin
leukemia
retroviru
gammaretroviru
extens
studi
vector
packag
kb
stabli
integr
genom
divid
cell
howev
integr
random
express
transgen
subject
silenc
target
effici
retrovir
vector
alter
greatli
improv
pseudotyp
vector
glycoprotein
envelop
virus
target
specif
cell
type
although
longterm
gene
express
well
gener
popul
genecorrect
cell
desir
outcom
gene
therapi
retrovirusbas
vector
shown
associ
high
probabl
insert
mutagenesi
due
random
integr
ex
vivo
phase
clinic
trial
xlink
scid
conduct
franc
unit
kingdom
bone
marrowderiv
cell
harvest
transduc
ex
vivo
gammaretrovir
vector
express
gamma
chain
reinfus
nine
infanttoddlerag
male
subject
franc
subject
unit
kingdom
therapeut
outcom
immedi
reconstitut
immun
system
observ
almost
subject
howev
unfortun
turn
event
subject
french
trial
subject
unit
kingdom
trial
develop
leukemialik
lymphoprolif
disord
link
retrovirusmedi
insert
mutagenesi
combin
seriou
advers
event
prompt
voluntari
hold
trial
lentivirus
group
retrovirus
belong
retrovirida
famili
unlik
retrovirusbas
vector
lentivir
lv
vector
transduc
quiescent
cell
consider
progress
made
develop
lv
vector
especi
base
human
immunodefici
viru
type
felin
immunodefici
viru
fiv
equin
infecti
anemia
viru
eiav
vector
disabl
render
safe
gene
transfer
vivo
develop
lv
vector
applic
specif
tissu
target
effici
enhanc
optim
envelop
pseudotyp
inde
lv
vector
pseudotyp
envelop
glycoprotein
vesicular
stomat
viru
mokola
sendai
ebola
baculoviru
protein
glycoprotein
sever
acut
respiratori
syndrom
avian
influenza
virus
shown
result
improv
transduct
variou
tissu
includ
hematopoiet
stem
cell
lung
eye
similar
adv
vector
lv
vector
larg
packag
capac
like
retrovirus
stabli
integr
genet
cargo
genom
host
cell
although
integr
random
lv
vector
result
longterm
transgen
express
subject
gene
silenc
mechan
varieti
tissu
includ
brain
muscl
lung
liver
eye
although
lv
vector
hold
great
promis
gene
transfer
vector
origin
especi
base
natur
rais
safeti
concern
great
care
taken
develop
lv
vector
system
design
safeti
featur
prevent
emerg
replic
compet
lentiviru
rcl
typic
accessori
gene
vif
vpr
vpu
nef
regulatori
gene
tat
rev
separ
gag
pol
env
gene
result
theoret
neglig
risk
emerg
rcl
share
pathogen
featur
parent
viru
safeti
lv
vector
improv
construct
selfinactiv
sin
lv
vector
clinic
lv
vector
shown
impress
efficaci
sin
lv
vector
use
transduc
ex
vivo
cell
isol
two
young
male
patient
suffer
xlink
adrenoleukodystrophi
ald
demyelin
disord
central
nervou
system
transduc
hematopoiet
stem
cell
reinfus
subject
diseas
progress
subject
halt
evid
mild
symptom
revers
observ
recent
ex
vivo
phase
clinic
trial
sin
lv
vector
express
link
signal
domain
use
transduc
ex
vivo
cell
harvest
subject
refractori
chronic
lymphocyt
leukemia
vectortr
cell
reinfus
subject
expand
level
result
complet
remiss
impress
data
form
basi
larger
clinic
trial
nonetheless
strict
attent
paid
risk
potenti
insert
mutagenesi
lv
vector
well
specif
ald
trial
investig
note
presenc
common
insert
site
ci
treat
cell
although
found
nongenotox
ci
real
risk
need
address
least
care
monitor
larger
clinic
trial
use
lv
vector
effici
nonvir
gene
transfer
vector
ie
lipoplex
use
deliv
gene
target
cell
larg
depend
mechan
present
target
cell
uptak
intracellular
transport
particl
nonviralbas
vector
system
effici
viralbas
vector
system
three
main
reason
limit
abil
cation
lipid
bind
surfac
target
cell
b
low
accumul
cation
lipiddna
complex
within
cell
c
ineffect
transloc
dna
nuclear
membran
nucleu
nonetheless
nonviralbas
vector
consid
safe
less
immunogen
viral
vector
current
activ
clinic
trial
worldwid
cf
airway
diseas
one
conduct
unit
kingdom
gene
therapi
consortium
use
cation
lipid
encapsul
cftrdna
deliveri
airway
cf
patient
year
older
earlier
clinic
trial
demonstr
deliveri
nebul
lung
cf
subject
correct
transport
defect
airway
although
beyond
scope
review
numer
virus
develop
gene
transfer
tool
includ
limit
vaccinia
viru
human
parainfluenza
viru
human
respiratori
syncyti
viru
alphaviru
herp
simplex
viru
well
physic
eg
electropor
magnetofect
chemic
eg
lipoplex
method
includ
rna
nanotechnolog
improv
vector
dna
deliveri
import
aspect
clinic
translat
gene
therapi
vector
evalu
vector
effici
safeti
relev
anim
model
vectormedi
correct
diseas
phenotyp
mous
model
form
basi
preclin
evalu
larger
anim
model
prior
clinic
trial
recent
year
challeng
translat
find
mous
studi
higher
anim
speci
even
human
becom
increasingli
appar
almost
imposs
predict
vector
behav
higher
anim
speci
let
alon
human
subject
reason
differ
gene
transfer
effici
heighten
immun
respons
speciesspecif
differ
vector
target
uptak
process
target
cell
well
complex
sophist
immun
system
higher
speci
one
excel
exampl
discrep
effici
safeti
observ
anim
model
human
subject
recent
hemophilia
b
trial
use
vector
longterm
gene
transfer
studi
larg
canin
nonhuman
primat
predict
therapeut
dose
vector
genomeskg
would
effect
restor
adequ
level
serumcircul
level
factor
ix
fix
howev
follow
liverdirect
inject
vector
adult
subject
hemophilia
b
transient
express
fix
observ
reason
appar
discrep
entir
understood
howev
postul
memori
cell
capsid
combin
compromis
liver
microenviron
patient
hemophilia
b
becom
infect
hepat
b
c
contribut
unpredict
cytolyt
capsiddirect
cell
respons
current
clinic
trial
hemophilia
b
employ
two
differ
strategi
shortterm
immunosuppress
selfcomplementari
lower
vector
dose
absenc
immunosuppress
addit
also
shown
immunogen
inject
intramuscularli
human
specif
clinic
trial
lpl
defici
subject
inject
intramuscularli
higher
vector
dose
capsidspecif
cell
detect
anoth
clinic
trial
use
express
subject
defici
cell
activ
capsid
follow
intramuscular
inject
vector
also
note
addit
humor
cellular
respons
viral
capsid
gene
therapi
carri
risk
activ
immun
system
wildtyp
version
miss
mutat
protein
signific
frequenc
circul
transgenespecif
cell
report
subject
treat
aav
vector
variou
diseas
includ
defici
dmd
recent
report
gene
replac
therapi
dmd
suggest
subject
may
increas
risk
clinic
meaning
cytotox
cell
respons
transgenederiv
dystrophin
protein
due
preexist
memori
cell
dystrophin
author
conclud
prime
cell
may
contribut
dmd
pathogenesi
enhanc
problemat
cell
respons
follow
gene
therapi
aim
reconstitut
normal
dystrophin
express
concern
howev
applic
gene
therapi
vector
human
subject
may
preval
preexist
cell
therapeut
gene
report
dystrophin
recent
cftr
reason
preexist
cell
present
patient
specif
genet
diseas
remain
elucid
nonetheless
role
resid
transgenespecif
cell
diseas
pathogenesi
possibl
increas
likelihood
reject
transduc
target
cell
follow
gene
therapi
need
care
investig
predict
cell
activ
human
follow
gene
therapi
consid
top
prioriti
prior
exposur
aav
anoth
viru
andor
compromis
heighten
immun
system
result
specif
diseas
phenotyp
may
contribut
likelihood
cell
activ
follow
gene
therapi
remain
proven
despit
limit
translat
liver
muscledirect
gene
therapi
two
exampl
anim
studi
accur
predict
vector
safeti
efficaci
appar
clinic
trial
lca
dose
safeti
profil
therapeut
outcom
vector
young
adult
human
subject
success
mirror
find
small
larg
anim
studi
major
patient
suffer
common
genet
diseas
diagnos
prenat
famili
histori
soon
birth
part
standard
postnat
screen
includ
cf
blood
cell
disord
inborn
error
amino
acid
metabol
eg
phenylketonuria
ii
organ
acid
metabol
iii
fatti
acid
metabol
howev
gene
therapi
clinic
trial
focu
treat
adult
subject
diseas
progress
caus
irrevers
damag
target
tissu
although
continu
strong
ethic
debat
regard
gene
therapi
fetus
andor
young
children
signific
progress
pre
postnat
gene
therapi
variou
anim
speci
includ
macaqu
demonstr
safeti
efficaci
specif
excit
data
aav
gene
transfer
studi
conduct
utero
shortli
birth
larg
anim
model
macaqu
pave
way
prenat
gene
therapi
genet
diseas
acut
immedi
lifeshorten
symptom
two
exampl
ornithin
transcarbamylas
defici
caus
irrevers
damag
young
male
babi
soon
birth
subject
die
within
week
birth
type
mucopolysaccharidos
irrevers
brain
damag
occur
prior
soon
birth
young
subject
therapeut
benefit
gene
transfer
prior
prenat
immedi
follow
postnat
birth
would
immedi
allow
prolong
life
improv
qualiti
life
gene
therapi
fetus
babi
diagnos
genet
diseas
cf
dmd
also
warrant
level
damag
affect
tissu
birth
minim
benefit
earli
therapeut
gene
express
target
tissu
maxim
logist
limit
vector
dose
need
inject
minim
given
small
size
babi
kg
although
debat
surround
impact
serumcircul
neutral
antibodi
babi
recent
data
gener
macaqu
demonstr
matern
aavspecif
antibodi
pass
babi
via
umbil
cord
crossneutr
vector
decreas
effici
gene
transfer
nonetheless
prenat
gene
therapi
take
advantag
immatur
immun
system
remain
ignor
express
foreign
antigen
allow
induct
toler
therapeut
protein
longterm
gene
express
continu
work
prenat
postnat
gene
transfer
aav
lentivir
vector
focus
improv
gene
transfer
increas
safeti
reduc
risk
germ
line
transmiss
true
potenti
gene
therapi
realiz
recent
patient
suffer
inherit
recess
diseas
blind
lca
mutat
thirteen
differ
gene
associ
lca
mutat
retina
pigment
epitheliumspecif
protein
account
lca
suffer
restor
vision
mous
dog
model
form
basi
three
separ
clinic
trial
unit
state
unit
kingdom
aim
restor
vision
subject
lca
result
mutat
improv
visual
function
evid
within
week
vector
inject
remark
result
vision
restor
young
subject
reestablish
hope
increas
expect
gene
therapi
realist
deliv
aav
vector
plethora
serotyp
current
avail
posit
aav
key
player
virusbas
gene
therapi
clinic
trial
inde
major
current
activ
clinic
trial
make
use
aav
vector
specif
vector
clinic
gene
therapi
hemophilia
b
vector
defici
muscular
dystrophi
type
lpl
defici
pomp
diseas
sever
heart
failur
batten
diseas
sanfilippo
syndrom
type
hemophilia
b
lca
agerel
macular
degener
alzheim
diseas
canavan
diseas
parkinson
diseas
expand
list
activ
clinic
trial
use
gene
transfer
vector
found
http
clinicaltrialsgov
trial
conduct
europ
australia
http
wwwclinicaltrialsregistereu
http
wwwabediacomwiley
complet
human
genom
project
came
much
specul
innumer
prospect
use
newli
discov
genet
inform
genet
predisposit
acquir
diseas
allow
develop
aggress
earli
intervent
prevent
morbid
mortal
associ
particular
diseas
vein
greatest
potenti
sequenc
human
genom
coupl
avail
highli
effici
vector
person
medicin
acquir
eg
cancer
genet
predisposit
eg
diabet
heart
diseas
condit
recent
success
gene
therapi
clinic
trial
long
overdu
serv
refocu
attent
build
palpat
excit
around
incred
promis
multipl
clinic
trial
unit
state
europ
current
recruit
subject
genet
diseas
includ
dmd
hemophilia
b
diseas
affect
vision
gene
therapi
readi
primetim
predict
next
year
field
wit
mani
clinic
success
